Company intelligence / Profile preview

InvaGen Therapeutics

Hauppauge, New York, United States

Ownership: Private
Employees: ~500
Development stage: Other

Overview

InvaGen Pharmaceuticals is a commercial-stage generic pharmaceutical company with 32 marketed products and approximately 40 approved ANDAs. The company has 30 pipeline products expected to be approved over subsequent years and has filed 5 first-to-file products.

Therapeutic areas: CardiovascularImmunologyEndocrinologyInfectious DiseasesNeurologyPsychiatryOncology
Modalities: Small moleculeSynthetic peptide
Industry: Biotech

Partnerships

Acquisition agreement with Avenue Therapeutics for IV Tramadol development and commercialization, with InvaGen acquiring 33.3% stake for $35 million followed by remaining shares for up to $180 million

Beyond the preview

Go deeper on InvaGen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InvaGen Therapeutics.

Explore the full profile